TABLE V.
Most frequent grade 3 or 4 treatment-emergent adverse events resulting in dose delay
| Event | iNHL patients [n (%) by cycle length] | CLL patients [n (%) by age] | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| 21 Days (n=16) | 28 Days (n=58) | Overall (n=74) | <70 Years (n=9) | ≥70 Years (n=7) | Overall (n=16) | |
| Any event | 8 (50.0) | 14 (24.1) | 22 (29.7) | 3 (33.3) | 3 (42.9) | 6 (37.5) |
| Neutropenia | 4 (25.0) | 4 (6.9) | 8 (10.8) | 0 | 1 (14.3) | 1 (6.3) |
| Decreased neutrophil count | 0 | 4 (6.9) | 4 (5.4) | 1 (11.1) | 0 | 1 (6.3) |
| Decreased platelet count | 0 | 4 (6.9) | 4 (5.4) | NA | NA | NA |
| Anemia | 1 (6.3) | 2 (3.4) | 3 (4.1) | 1 (11.1) | 0 | 1 (6.3) |
| Infections and infestations | 1 (6.3) | 2 (3.4) | 3 (4.1) | NA | NA | NA |
| Fatigue | 1 (6.3) | 1 (1.7) | 2 (2.7) | NA | NA | NA |
| Hemolysis | NA | NA | NA | 0 | 1 (14.3) | 1 (6.3) |
| Thrombocytopenia | 1 (6.3) | 0 | 1 (1.4) | 0 | 1 (14.3) | 1 (6.3) |
| Papular rash | NA | NA | NA | 1 (11.1) | 0 | 1 (6.3) |
iNHL = indolent non-Hodgkin lymphoma; CLL = chronic lymphocytic leukemia; NA = not applicable.